This study assesses how collaboration between Lebanon's Ministry of Public Health (MoPH), Agence Française de Développement (AFD) and ESA Business School (ESA) strengthened the pharmaceutical regulatory framework during severe crises. It reviews the design and outcomes of reforms in governance, pharmacovigilance and quality assurance; identifies key enabling and limiting factors and draws lessons for other low- and middle-income countries (LMICs).